An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients with Membranous (Class V) Lupus Nephritis
A study for patients with Lupus Nephritis using ACTHAR GEL
Sponsor: Questcor Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAM4152
U.S. Govt. ID: NCT01926054
Contact: Wooin Ahn: 212-305-0320 /
Additional Study Information: The purpose of this study is to determine if Acthar gel is a safe and effective therapy for patients with membranous (Class V) lupus nephritis. Class V lupus nephritis is associated with the development of chronic kidney disease and end-stage renal (kidney) disease, and there is no clear therapy for treatment. Currently used therapies arent completely effective in causing a decrease in symptoms of Class V lupus nephritis. In this study the safety of two different doses of Acthar gel and its ability to decrease the symptoms of Class V lupus nephritis will be assessed with the goal of determining whether Acthar gel is an effective and safe treatment for Class V lupus nephritis.
This study is closed
Wooin Ahn, MD
Do You Qualify?
Do you have hepatitis B, C, HIV, TB or any other active and chronic infections? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Wooin Ahn